University of Washington

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, March 11, 2024

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
  • Research and development expenses were $40.5 million for the year ended December 31, 2023, compared to $62.5 million for 2022.
  • 2023 and Recent Corporate Highlights:
    In July 2023, Mustang announced that it amended its previously announced asset purchase agreement with uBriGene (Boston) Biosciences Inc. (“uBriGene”) and closed the transaction.
  • In October 2023, Mustang completed a registered direct offering priced at-the-market for approximately $4.4 million in gross proceeds.

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Retrieved on: 
Thursday, February 29, 2024

The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.

Key Points: 
  • The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.
  • These data will be presented during the 28th Annual International Congress on Hematologic Malignancies® in Miami from February 29 - March 3.
  • “Head-to-head randomized clinical trials are the gold standard when it comes to evaluating the potential impact of individual treatments for patients.
  • The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.

Westlake Royal Building Products™ to Showcase Be Boundless™ Campaign, Top Industry Trends and New Product Innovations at 2024 International Builders’ Show

Retrieved on: 
Monday, February 26, 2024

Westlake Royal Building Products ™ (Westlake Royal), a Westlake company (NYSE:WLK), will showcase its Be Boundless™ campaign, top industry trends and new product innovations at the 2024 NAHB International Builders’ Show ® (IBS) in Las Vegas from February 27-29, 2024.

Key Points: 
  • Westlake Royal Building Products ™ (Westlake Royal), a Westlake company (NYSE:WLK), will showcase its Be Boundless™ campaign, top industry trends and new product innovations at the 2024 NAHB International Builders’ Show ® (IBS) in Las Vegas from February 27-29, 2024.
  • Homeowners and building pros face complex product selection decisions—navigating around the areas of regional weatherability, performance and sustainability.
  • To meet these varied and evolving needs, Westlake Royal Building Products is exploring every innovation, from new easy-to-install products to support services.
  • At IBS 2024, Westlake Royal will showcase several new colors, profiles and products as part of its Siding & Accessories offerings:
    NEW!

The Ad Council, Coalition of Health Systems and Hospitals Tackle America's Most Urgent Public Health Crisis: Gun Violence

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 /PRNewswire/ -- Today at Northwell Health's 5th annual Gun Violence Prevention Forum, the Ad Council announced a new gun violence prevention initiative in collaboration with a coalition of health care leaders to address this urgent public health crisis and its impact on youth.

Key Points: 
  • This group of chief executives represents some of the nation's largest health systems and hospitals that are providing funding, strategic insight and issue expertise on gun violence prevention for the campaign.
  • However, only 26% selected gun injuries as the leading cause of death among children, demonstrating a need for further education.
  • Health systems and hospitals throughout the country have seen firsthand the toll gun violence takes on communities.
  • This includes a coalition-based and multi-audience approach, mobilizing the advertising, media and marketing industries to tackle gun violence prevention in America.

Argonne and other institutions report first-ever atomic freeze frame of liquid water

Retrieved on: 
Friday, February 16, 2024

Their study, recently published in the journal Science , built on the new science of attosecond physics, recognized with the 2023 Nobel Prize in Physics.

Key Points: 
  • Their study, recently published in the journal Science , built on the new science of attosecond physics, recognized with the 2023 Nobel Prize in Physics.
  • The study sample was a stream of liquid water, chosen as a model molecule in this first-ever experiment.
  • This allowed them to take a fingerprint of the electronic response following ionization in liquid water, all before the bulkier hydrogen atoms have time to move.
  • The findings demonstrate that a longstanding measurement of the structure of liquid water has been misinterpreted.

TalkLife secures new investment from TELUS to improve mental health support

Retrieved on: 
Thursday, February 8, 2024

Amid a global mental health crisis, TELUS is exploring new, innovative ways to make mental health support more accessible by partnering with peer support platform TalkLife creating a safe space for people to connect

Key Points: 
  • Amid a global mental health crisis, TELUS is exploring new, innovative ways to make mental health support more accessible by partnering with peer support platform TalkLife creating a safe space for people to connect
    VANCOUVER, BC and BRISTOL, England, Feb. 8, 2024 /PRNewswire/ - UK-based scaleup TalkLife , an innovative global online peer support community for people to talk about their mental health, has secured a capital investment from TELUS Ventures, the investment arm of world-leading communications technology company, TELUS.
  • TalkLife is also a valued partner of TELUS Health , a global healthcare leader supporting over 69 million lives worldwide.
  • "TalkLife is pioneering a new kind of mental health support that's accessible, relevant, and has the research backing to prove that it really works.
  • It will contribute to scale operations, and cement TalkLife's place as the leading peer provider of mental health support globally, helping those who might struggle to access traditional mental health support because of stigma, cost, or availability.

Juniper Networks Unveils Industry’s First AI-Native Networking Platform to Deliver Exceptional User Experiences and Lower Operational Costs

Retrieved on: 
Monday, January 29, 2024

Juniper Networks ® (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced the industry's first AI-Native Networking Platform, purpose-built to leverage AI to assure the best end-to-end operator and end-user experiences.

Key Points: 
  • Juniper Networks ® (NYSE: JNPR), a leader in secure, AI-Native Networking, today announced the industry's first AI-Native Networking Platform, purpose-built to leverage AI to assure the best end-to-end operator and end-user experiences.
  • Unique to the industry, Juniper’s AI-Native Networking Platform unifies all campus, branch and data center networking solutions with a common AI engine and Marvis Virtual Network Assistant (VNA).
  • “AI is the biggest technology inflection point since the internet itself, and its ongoing impact on networking cannot be understated.
  • Our AI-Native Networking Platform represents a bold new direction for Juniper, and for our industry.

USPS Roars Into Lunar New Year With New Stamp

Retrieved on: 
Thursday, January 25, 2024

SEATTLE, Jan. 25, 2024 /PRNewswire/ -- Today, the U.S. Postal Service unveiled the Lunar New Year: Year of the Dragon Forever stamp in the historic Chinatown - International District in Seattle. The Postal Service printed 22 million stamps that are now on sale at Post Offices and usps.com.

Key Points: 
  • Postal Service unveiled the Lunar New Year: Year of the Dragon Forever stamp in the historic Chinatown - International District in Seattle.
  • This stamp is a great example that reflects our nation's rich, multicultural heritage and traditions."
  • "The Lunar New Year: Year of the Dragon stamp is much more than U.S. postage," said Tan, the Wing Luke Museum executive director.
  • For USPS media resources, including broadcast-quality video and audio and photo stills, visit the USPS Newsroom .

Medical Education Market size to grow by USD 208.73 billion from 2022 to 2027, Market is fragmented due to the presence of prominent companies like All India Institute of Medical Sciences, KP Bernard J. Tyson School of Medicine and Mayo Clinic, and many m

Retrieved on: 
Friday, January 5, 2024

The medical education market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The medical education market is fragmented owing to the presence of many global and regional companies.
  • Download a Sample before buying
    KP Bernard J. Tyson School of Medicine - The company offers medical education such as a Bachelor of Science (BS) in Health Sciences.
  • National University of Singapore - The company offers medical education such as M.D.M.B.A., M.D.Ph.D., M.D.M.P.H., and M.D.MSHCM, and others.
  • The higher education testing and assessment market is estimated to grow at a CAGR of 6.32% between 2022 and 2027.

Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023

WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced updated encouraging safety and efficacy data from Mustang’s multicenter Phase 1/2 clinical trial of MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”). The data were presented during a poster session on December 9th (Abstract #2102) at the 65th American Society of Hematology (“ASH”) Annual Meeting and build upon previously reported data from a single-institution Phase 1/2 clinical trial conducted at Fred Hutchinson Cancer Center (“Fred Hutch”). MB-106 is being developed in a collaboration between Mustang and Fred Hutch.

Key Points: 
  • The data were presented during a poster session on December 9th (Abstract #2102) at the 65th American Society of Hematology (“ASH”) Annual Meeting and build upon previously reported data from a single-institution Phase 1/2 clinical trial conducted at Fred Hutchinson Cancer Center (“Fred Hutch”).
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutch.
  • “All nine patients have responded clinically to treatment in this multicenter trial and the safety and efficacy profile of MB-106 appears to be consistent with the original single-institution trial.
  • It is especially encouraging that complete responses were observed in all patients with follicular lymphoma in this multicenter trial,” said Mazyar Shadman, M.D., M.P.H., Study Chair, Innovators Network Endowed Chair at Fred Hutch, Associate Professor and physician at Fred Hutch and University of Washington.